How Bilastine is Used to Treat Allergic Rhinitis and Urticaria in Children

Abstract

Management guidelines for allergic rhinitis and urticaria recommend oral second-generation antihistamines as first-line treatment. The efficacy and safety of bilastine, the newest nonsedating second-generation antihistamine, are well established in adolescents/adults with these allergic conditions. The bilastine development program for pediatric use (2–<12 years) followed EMA-authorized processes. Pharmacokinetic/pharmacodynamic simulation and modeling and a pharmacokinetic study were conducted to identify and confirm the pediatric dose (10 mg/day). A Phase III, multicenter, double-blind, randomized, placebo-controlled, parallel-group study was performed to confirm the safety of bilastine 10 mg/day in children. In this article, evidence is reviewed for use of bilastine in children with allergic rhinoconjunctivitis or urticaria. Several cases are presented which demonstrate its role in routine clinical practice.

An emerging antihistamine drug with multiple therapeutic benefits: Bilastine

“…It was approved in the European Union in 2010 for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria in adolescents and adults 5 . Recently, it has been approved for use in children aged up to 12 years [6][7] . It has been used in over 120 countries worldwide 8 but its use in the US market-related literature is not available in the public domain.…”